In Vitro Trials

$23M capped ALA partners with $1.1BN Imugene - Now Targeting 90% of Cancers

Next Investors Sep 27, 2022

Yesterday, Arovella Therapeutics (ASX:ALA) announced that it had signed a partnership agreement with $1.1BN capped Imugene to develop its technology to target solid tumour cancer cells.

Neurotech’s key near-term objectives

Finfeed Archived Jan 21, 2021

Neurotech International Limited (ASX: NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered.